NeuroVax

Spelman Research Initiates Coverage of The Immune Response ...
Earthtimes.org - USA
In the Spelman report, Mr. Mitu writes, "The drug candidates -- IR103 (HIV) and NeuroVax(TM) (MS) -- are based on innovative technologies that do not have ...

---

FTY720

Pharma Sector: Few Newsmakers Of The Week - Novartis, Abbott ...
Trading Markets - Los Angeles,CA,USA
... Novartis' FTY720, which is in phase III trial could become the first oral therapy for multiple sclerosis if the company files for approval of the drug in 2009 ...

---

Tysabri

Elan loss rises as it misses Q3 sales targets
Unison.ie - Bray,Ireland
... Revenue at Elan, which reintroduced its multiple sclerosis treatment Tysabri in the summer, fell 4pc to $123.3m. The company began ...

Elan improves full-year guidance; to file Tysabri for Crohn's by ...
Forbes - NY,USA
LONDON (AFX) - Elan Corp said it expects annual losses, excluding the cost of relaunching Multiple Sclerosis treatment Tysabri, to be smaller than previously ...

---